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TRAIL death receptors DR4 and DR5 mediate cerebral
microvascular endothelial cell apoptosis induced by
oligomeric Alzheimer’s Ab
S Fossati
1, J Ghiso
1,2 and A Rostagno*
,1
Vascular deposition of amyloid-b (Ab) in sporadic and familial Alzheimer’s disease, through poorly understood molecular
mechanisms, leads to focal ischemia, alterations in cerebral blood ﬂow, and cerebral micro-/macro-hemorrhages, signiﬁcantly
contributing to cognitive impairment. Here, we show that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death
receptors DR4 and DR5 speciﬁcally mediate oligomeric Ab induction of extrinsic apoptotic pathways in human microvascular
cerebral endothelial cells with activation of both caspase-8 and caspase-9. The caspase-8 inhibitor cellular FLICE-like inhibitory
protein (cFLIP) is downregulated, and mitochondrial paths are engaged through BH3-interacting domain death agonist (Bid)
cleavage. Upregulation of DR4 and DR5 and colocalization with Ab at the cell membrane suggests their involvement as initiators
ofthe apoptotic machinery. Direct binding assaysusing receptor chimeras conﬁrm the speciﬁc interactionofoligomeric Abwith
DR4 and DR5 whereas apoptosis protection achieved through RNA silencing of both receptors highlights their active role in
downstream apoptotic pathways unveiling new targets for therapeutic intervention.
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The deposition of amyloid-b (Ab) in and around cerebral
vessels, known as cerebral amyloid angiopathy (CAA), is a
condition present in normal aging and in more than 80% of
Alzheimer’s disease (AD) patients. CAA compromises med-
ium- and small-size arteries and arterioles as well as capillary
endothelium affecting cerebral blood ﬂow and altering the
properties of the blood brain barrier, events which in turn
cause degeneration of the entire neurovascular unit.
1 There-
fore, it is not surprising that CAA is now considered a
signiﬁcant contributor to cognitive decline, and dementia
being increasingly recognized as a major factor in AD
pathogenesis.
2 To date, several mechanisms have been
proposed as the source of the vascular Ab deposits including
derivation from circulating blood and local production by
vessel-wall cells.
3,4 While production of Ab by vascular cells
has been clearly demonstrated, the development of trans-
genic models with several fold increased levels of plasma Ab,
albeit failing to exhibit brain lesions, argue against the
likelihood of a blood origin for brain Ab. An emerging body
of evidence indicates that neuronally originated Ab is mainly
cleared through the blood–brain and brain–cerebrospinal
ﬂuid barriers, degraded by resident enzymes, and secreted
into the extracellular space entering the perivascular drainage
route along with the bulk ﬂow of extracellular ﬂuid, mostly at
the level of capillaries or arterioles. This perivascular
clearance has a key role in the development of CAA; impaired
drainage owing to Ab accumulation, as well as age-related
ﬁbrotic changes in the cerebral vasculature clearly impact the
severity of CAA.
Previous data from our lab demonstrated that Ab induces
caspase-mediated mitochondrial apoptosis in cerebral micro-
vascularsmoothmuscleandendothelialcells(ECs),bothwith
potential to be in direct contact with Ab vascular deposits
in vivo under pathological conditions. This effect is exacer-
bated by the presence of speciﬁc mutations at positions 22 or
34 (E22Q and L34V), known to cause cerebral hemorrhage in
familial forms of CAA (human cerebral hemorrhage with
amyloidosis Dutch and Piedmont type, respectively).
5
Apoptotic cell death typically involves two distinct pathways
– the Bcl-2-regulated intrinsic path and the death-receptor-
mediated extrinsic mechanism – both translating in morpho-
logical and biochemical changes associated with the apopto-
tic phenotype. The extrinsic pathway classically begins with
the binding of an appropriate ligand to a subset of tumor
necrosis factor (TNF) receptor superfamily (TNFRSF) mem-
bers: the death receptors.
6 These transmembrane receptors,
containingaconserveddeathdomain,
7recruittheintracellular
adaptor molecule FADD (Fas-associated protein with death
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www.nature.com/cddisdomain), which in turn binds to and activates caspase-8,
inducing the formation of DISC (death-inducing signaling
complex), to initiate apoptosis. This pathway is regulated by
cellular FLICE-like inhibitory protein (cFLIP), crucial for the
modulation of death signaling through interaction with
procaspase-8 at DISC.
6,8 Caspase activation is generally
ampliﬁed by engagement of the mitochondrial intrinsic path-
way through caspase-8 processing of Bid (BH3-interacting
domain death agonist).
9 Cleaved/truncated Bid (tBid) inter-
acts with other Bcl-2 family members on the surface of the
mitochondria, resulting in mitochondria outer membrane
permeabilization, release of cytochrome c, and subsequent
caspase-9 activation. Both caspase-8 and -9 cause down-
stream activation of the effector caspase-3.
Members of the death receptor family include Fas, TNFR1
(tumor necrosis factor receptor 1), the TRAIL (TNF-related
apoptosis-inducing ligand) death receptors 4 and 5 (DR4 and
DR5), DR3, DR6, and p75/NGFR (nerve growth factor
receptor). Our study unveiled for the ﬁrst time the contribution
of DR4 and DR5 to the apoptotic mechanisms elicited by
oligomeric Ab on cerebral microvascular ECs, providing
insights into the signaling pathways triggered through their
activation and validating their active role in Ab-mediated
apoptosisviaRNAsilencing. Overall,our resultsshow adirect
binding of oligomeric Ab to DR4 and DR5 leading to their
subsequent activation and downstream apoptosis induction,
and point out to TRAIL death receptor-mediated paths as
novel therapeutic targets for neurovascular degeneration in
AD as well as in sporadic and familial CAA.
Results
Caspase-8 activation is an early event in Ab-induced EC
apoptosis. Challenge of cerebral microvascular ECs with
vasculotropic Ab variants triggers the apoptotic cascade,
as evidenced by changes in the cell morphology, DNA
fragmentation, release of mitochondrial cytochrome c to
the cytoplasm, and phosphatidylserine membrane trans-
location with annexin V-positive ﬂuorescence (Fossati et al.
5,
Viana et al.
10 and Supplementary Figure 1). The participation
of caspase-8 and -9 in Ab-induced apoptosis was analyzed in
cerebral EC challenged 0–24h with Ab synthetic homologs.
AbE22Q was added to the cells immediately after solubiliza-
tion, while Ab-WT and AbL34V, owing to their slower aggre-
gation kinetics, were pre-aggregated (3 days, 371C) before
addition to the cell cultures to allow the formation of
oligomers, considered the species responsible for cell toxicity
in our model.
5 In all cases, activation of both caspases was
evident after only few hours of peptide challenge (Figure 1a)
although the time course of activation suggests a slower
kinetics or lower intensity for caspase-9. Corroborating the
speciﬁcity of the cellular responses, the reverse sequence
Ab40-1 peptide, in difference to Ab-WT, was unable to trigger
EC apoptosis or to induce activation of caspase-8 and
caspase-9 under the conditions tested (Supplementary
Figure 2).
The early detection of caspase-8 activation suggested the
involvement of death receptors, known to trigger apoptosis
through the engagement of this protease, with downstream
activation of caspase-9, subsequent to cytochrome c release
to the cytoplasm. Further demonstration of the primary
involvement of the extrinsic apoptotic pathway was assessed
through evaluation of the expression of c-FLIP and Bid by
western blot (WB). Figure 1b illustrates a clear decrease in
c-FLIP, a protein inhibiting procaspase-8 processing and
known to be downregulated in death receptor activation.
7
Downregulation of c-FLIP was evident after 8-h incubation
with AbE22Q and was maintained for24h. This decrease was
also observed in cells challenged 24h with AbL34V and
3 days with Ab-WT, consistent with the time frame of apop-
tosis induction by these peptides.
5 The involvement of the
receptor-mediated apoptotic pathway was further evaluated
through analysis of the cleavage of Bid that, upon processing
by caspase-8, engages mitochondrial pathways inducing
caspase-9 activation.
11 Bid cleavage was demonstrated
by the reduction of the 20-kDa full-length Bid in EC treated
8–16h with AbE22Q, or 3 days with AbL34V and Ab-WT
(Figure 1c). Corroborating caspase participation in Bid cleavage,
co-incubation of AbE22Q with the pan-caspase inhibitor
ZVAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-ﬂuoromethyl-
ketone;100mM, ENZO Life Sciences, Farmingdale, NY, USA)
re-established the levels of the 16-kDa tBid to those of
untreated controls (Figure 1d) while not affecting c-FLIP,
which can be downregulated independently of caspase
activation.
8
Ab homologs induce overexpression of apoptosis
mediators and death receptors in ECs. The differential
expression of apoptosis-related genes elicited by challenging
EC with AbE22Q was evaluated using pathway-speciﬁc PCR
arrays. Supplementary Table 1 illustrates all genes analyzed
and the pertinent fold change at 6-h challenge; genes that
were modiﬁed by Z±1.3-fold in three separate experiments
are highlighted in Figure 2a. The changes include transla-
tional upregulation of several cytoplasmic apoptosis media-
tors, like APAF-1, a protein containing a caspase recruitment
domain (CARD) that is necessary for the formation of the
apoptosome and the activation of caspase-9, the Bcl-2 family
member Bcl-2-like protein 2 (also known as Bcl2-W), the
apoptosis inducer BIK (also known as Bcl-2-interacting
killer), and the CARD-containing microtubule-associated
protein CARD6, implicated in the positive modulation of
NF-kB signaling. The members of the tumor necrosis factor
ligand superfamily found upregulated in the arrays were TNF
superfamily member 1 (TNFSF1, also known as TNF-b,a
highly inducible cytokine with proinﬂammatory effects) and
CD70 (also known as CD27 ligand or tumor necrosis factor
ligand superfamily member 7), a cytokine with homology to
TNF classically involved in cell proliferation.
Among the receptors affected by Ab challenge, and
illustratedinFigure2abyblackbars,ourresultsdemonstrated
upregulationofmembersoftheTNFRSF,includingTNFRSF5
(also known as CD40), essential in mediating inﬂammation-
related responses, as well as TNFRSF25, TNFRSF10A, and
TNFRSF10B. The ﬁrst one, also known as DR3, typically
activated by the ligand TL1A and signaling through the
adapter protein TRADD (TNFR1-associated death domain
protein),
12 is mainly associated with inﬂammation-related
processes,
6 including production of cytokines and inﬂam-
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Cell Death and Diseasematory mediators such as TNFa, MCP-1, and IL-8.
13,14
TNFRSF10A (known as DR4 or TRAILR1) and TNFRSF10B
(known as DR5 or TRAILR2), both highlighted by the red box
in Figure 2a, are characteristically activated by TRAIL/
TNFSF10.
Based on our data illustrated in Figure 1, indicating that Ab-
induced apoptosis involved initial activation of caspase-8 with
decrease of c-FLIP, suggestive of primary involvement of
death receptors engaging the adaptor molecule FADD, we
focused our attention on the upregulation of the TRAIL
receptors DR4 and DR5, known to be expressed in EC and
throughout the brain.
15,16 Quantitative real-time PCR (RT-
PCR) for these genes in EC treated 3–24h with AbE22Q
(Figure 2b) showed that DR4 overexpression was evident
after 3-h challenge and continued to increase for 24h. DR5
overexpression was observed starting at 6h and the levels,
reaching twofold increase over untreated controls, as in the
case of DR4, were maintained for the 24h duration of the
experiment (Figure 2c). DR4 and DR5 upregulation was
additionally observed after 3-day EC challenge with Ab-WT
and -L34V, albeit reaching lower levels than for AbE22Q,
consistent with the attenuated intensity of the apoptotic
response induced by these peptides
5 (Figures 2d and e).
Ab colocalization with DR4 and DR5 on EC membranes.
Conﬁrmation of DR4 and DR5 overexpression and assess-
ment of possible colocalization with Ab peptides was
performed by immunocytochemistry and confocal micro-
scopy. AbE22Q 24-h treatment induced a clear overexpres-
sion of DR4 and its colocalization on the plasma membrane
with Ab, as indicated in Figure 3 by overlapping of the
respective ﬂuorescent signals. DR4 upregulation was also
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Figure 1 Caspase-8 and caspase-9 activation in Ab-challenged microvascular ECs. (a) Activation of caspase-8 and -9 was monitored via luminescent assays in ECs
challenged up to 24h with Ab-E22Q (Q22, 50mM, freshly solubilized), as well as with Ab-L34V (V34) and Ab-WT (50mM, both pre-aggregated 3 days in EBM-2 medium).
Results represent the mean±S.D. of three independent experiments. (b) Downregulation of the endogenous caspase-8 inhibitor cFLIP was observed after 8, 16, and 24h
treatment with Ab-E22Q (Q22). cFLIP decrease was also observed after 1-day treatment with Ab-L34V (V34) and 3-day challenge with Ab-WT. (c) Depletion of 20kDa
full-lengthBidwasevidentafterECtreatmentwithAb-E22Qfor8and16haswellasafter3-daychallengewithAb-L34Vor-WT.(d)Thepan-caspaseinhibitorZVADreverted
the caspase-8-dependent cleavage of Bid as illustrated by the reduction of the 16-kDa tBid band intensity while not affecting levels of cFLIP. In b, c, and d, immunoreactivity
with GAPDH indicates equal protein loading, and lanes labeled C illustrate untreated control cells. In (d), graphs illustrate cFLIP and tBid band intensities – evaluated via
ImageJ – normalized to GAPDH
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Cell Death and Diseaseobserved after a more prolonged 3-day challenge with
Ab-WT and -L34V albeit with a ﬂuorescent signal of lower
intensity than the one elicited by AbE22Q, in agreement with
the qPCR data for DR4 mRNA (Figure 2). For both Ab-WT
and -L34V treatments, colocalization of DR4 with the
respective amyloid peptides was also observed (Figure 3,
central and lower panels). Immunostaining of DR5 after 24-h
challenge with E22Q showed increase in the ﬂuorescent
signal, consistent with the qPCR data, and partial colocaliza-
tion with the peptide (Figure 4). In the case of Ab-WT and
L34V peptides, a 3-day challenge did not result in a clear
increase of the receptor ﬂuorescent signal, consistent with
the minimal B1.25-fold increase expression evaluated by
qRT-PCR (Figure 2). Likewise, colocalization of DR5 with the
respective peptides was not evident (Figure 4 central and
lower panel).
Further elucidation of the relationship between DR4
upregulation at the cell membrane and Ab colocalization, as
well as conﬁrmation of the time frame required for the
receptor’s increased expression, was assessed by immuno-
staining after a short-time challenge (2–8h). Notably, the
receptor colocalized at all time points with the peptide.
Furthermore, DR4 expression increased in parallel with the
peptide membrane localization (Figure 5), suggesting a direct
bindingofAbtothereceptor.Toruleoutthepossibilitythatthe
observed DR4 and DR5 upregulation was driven by their
canonical ligand, TRAIL, this protein was quantitated by
ELISA in EC culture supernatants and lysates after challenge
with AbE22Q, AbL34V, and Ab-WT. In all cases, the levels
of soluble TRAIL in the media or in the cell lysates were
below the 2.8pg/ml minimum detectable level of the assay
(data not shown), conﬁrming that, in our system, DR4 and
DR5upregulationwasindependentfromthepathwayselicited
by their classical ligand.
Ab40 variants bind DR4 and DR5 in vitro. The direct
binding of Ab to TRAIL death receptors was evaluated by
immunoprecipitation (IP) using chimeras constituted by the
extracellular portion of DR4 and DR5 fused to the immuno-
globulin G (IgG) Fc fragment (DR4/Fc and DR5/Fc). The Fc
fragment within the chimera allowed immobilization onto
paramagnetic beads coupled with Protein-G, and subse-
quent IP of the peptide species exhibiting speciﬁc binding for
the respective receptors. Binding of AbE22Q was performed
using freshly solubilized peptide, whereas binding of Ab-WT
and Ab-L34V, exhibiting slower oligomerization, was carried
out with freshly solubilized peptides as well as with 3-day pre-
aggregated preparations. In all cases, after non-denaturing
elution of the material bound to the receptor-coated beads,
both the eluted components and the original Ab prepara-
tions incubated with the beads (input) were separated by
native-gel electrophoresis, followed by WB. As illustrated
in Figure 6a left panel, consistent with previous studies,
5
freshly solubilized E22Q exhibited the presence of high
molecular mass (HMM) oligomers, in addition to the
abundant monomeric, dimeric, and tetrameric components.
Figure 6a right panel illustrates that in spite of the high
abundance of low molecular mass components, only dimers
and HMM aggregates of B150–350KDa (as estimated
by Fergusson plot analysis) displayed speciﬁc binding to
DR4 and, to a lower extent, DR5, in agreement with the
immunoﬂuorescence data (Figures 3 and 4). Notably, the
DR4/DR5-bound fraction is enriched in B350-KDa HMM
oligomers, which are minor components in the peptide
preparation, as evidenced by the absence of immuno-
reactivity in this molecular mass range in the input fraction.
No binding was observed to Fas chimeras or to Fc, used as
nonspeciﬁc binding control.
For Ab-WT and -L34V, no high-order oligomerization was
observed in fresh preparations, whereas 3-day incubation
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Figure 2 Upregulation of apoptosis mediators and death receptors in
microvascular ECs after Ab challenge. (a) Genes upregulated or downregulated
Z1.3 times following 6h EC challenge with Ab-E22Q evaluated via apoptosis-
speciﬁc PCR arrays (Superarray; SABiosciences). The changes include transla-
tional upregulation of several apoptosis mediators (light gray bars), members of the
TNF ligand superfamily (dark gray bars), and membrane receptors (black bars); red
boxhighlightsTNFRSFmembersinvolvingactivationof caspase-8 with decrease of
cFLIP and engaging the adapter protein FADD. (b and c) The expression of
TNFRSF10A and 10B (DR4 and DR5, respectively) was measured by quantitative
RT-PCR after EC challenge with Ab-E22Q (Q22) for 3, 6, and 24h. (d and e) DR4
and DR5 gene expression was evaluated after treatment with Ab-L34V (V34) and -
WT for 2 and 3 days. In (b–e) graphs represent fold of increase of DR4 and DR5
expression compared with untreated controls at the same time points. Results are
representativeofthreeseparateexperiments,eachoneperformedintriplicate.Bars
represent mean±S.D. of an independent triplicate experiment
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Cell Death and Diseaseresulted in the formation of HMM oligomers in addition to
the abundant low molecular mass species (Figures 6b and c,
left panels). Analysis of the material retained by the
beads demonstrated lack of binding to DR4 or DR5
of any of the species present in the freshly solubi-
lized preparations (Figures 6b and c, right panels).
Pre-aggregation resulted in a strong and speciﬁc binding
of Ab-L34V to DR4 and a lower interaction with DR5
(Figure 6b, right panel). As for E22Q, the Ab species
interacting with both receptors corresponded to HMM
oligomers (B150–350KDa). Comparable HMM species of
Ab-WT bound DR4 (Figure 6c), but not DR5 chimeras, likely
reﬂecting the lower afﬁnity interaction with this receptor.
Conﬁrming the speciﬁcity of Ab binding to DR4/DR5, the
receptorchimerasfailedtobind3-daypre-aggregatedreverse
sequence Ab40-1 (Figure 6d).
Cnt
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Figure 3 Confocal microscopy analysis of DR4 localization in Ab-challenged cerebral ECs. EC cultures were treated with Ab-E22Q (Q22) for 1 day and with Ab-L34V
(V34) and Ab-WT for 3 days. Localization of the respective Ab homologs and DR4 was evaluated by immunoﬂuorescence and analyzed by confocal microscopy.
Green staining represents DR4, red highlights Ab, and blue signal illustrates nuclei counterstained with TO-PRO. Bar represents 50mm
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Cell Death and DiseaseDR4 and DR5 silencing protects ECs from Ab-induced
apoptosis. Silencing RNA experiments were designed to
demonstrate the requirement of DR4 and DR5 as initiators
of the Ab-induced apoptotic machinery in EC. Transcripts of
the housekeeping genes GAPDH and Cyclophilin-B, used to
determine efﬁcacy and speciﬁcity of the silencing in the
difﬁcult to transfect EC, were reduced by 90% and 80%,
respectively, after 3-day silencing by the respective siRNAs
(Figure 7a), with no effect on the expression of the DRs, as
assessed by qRT-PCR. Expression of DR4 and DR5 mRNAs
was also successfully reduced by B75% after 3-day
incubation with the respective siRNAs with no noticeable
crossreactivity between both receptors. To determine the
effect of DR4 and DR5 silencing on Ab-induced apoptosis,
we measured the extent of nucleosome formation by cell
death ELISA after Ab-E22Q treatment in cells in which DR4
and DR5 were previously silenced. E22Q-accelerated EC
toxicity
17 allowed the evaluation of apoptosis in a time frame
Cnt
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Figure4 ConfocalmicroscopyanalysisofDR5localizationinAb-challengedcerebralECs.ECculturesweretreatedfor1daywithAb-E22Q(Q22)andfor3dayswithAb-
L34V (V34) and Ab-WT as in Figure 3. Localization of Ab peptides and DR5 was evaluated by immunoﬂuorescence and analyzed by confocal microscopy. Green staining
highlights DR5, red staining indicates Ab, and blue illustrates nuclei counterstained with TO-PRO. Bar represents 50mm
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Cell Death and Diseaseconsistent with the persistency of the transient receptor
silencing. Knocking down the expression of DR4, DR5, or
both, resulted in 60–70% protection from Ab-induced
apoptosis, in comparison with cells transfected with non-
silencing siRNA control (Figure 7b), conﬁrming the signiﬁcant
role played by DR4 and DR5 activation. Whether the lack of
total inhibition achieved by knocking down both receptors
reﬂects the absence of their total silencing in our system or
the involvement of additional receptors remains to be
elucidated. In this sense, it should be pointed out that
silencing of DR3 – the TNF receptor exhibiting comparable
upregulation in the PCR arrays (Supplementary Table 1 and
Figure 2a) – failed to prevent AbE22Q-mediated apoptosis
(Supplementary Figure S3), further strengthening the rele-
vance of DR4/DR5 pathways. Silencing the expression of
DR4 and DR5 additionally translated in signiﬁcant inhibition
of caspase-8 activation (Figure7c) once more highlighting the
relevance of these receptors in the Ab-elicited apoptotic
pathways.
Discussion
Ab accumulation around cerebral vessels is known to induce
degeneration of the entire neurovascular unit.
18 Previous
studies from our laboratory monitored the Ab-elicited
apoptotic events in cerebral microvascular cells demon-
strating induction of caspase-mediated mitochondrial path-
ways with Bax (Bcl-2-associated X protein) translocation
and cytochrome c release to the cytosol.
5,10 Prevention of
vessel-wall cell death through inhibition of cytochrome c
release or by the action of pan- and pathway-speciﬁc caspase
inhibitors provided a clear indication of the engagement of
both extrinsic and intrinsic apoptotic pathways either inde-
pendently or synergistically.
The results presented herein unveiled the participation of
death receptor-mediated pathways in Ab-induced EC apop-
tosis (illustrated in the diagram of Figure 8), as evidenced by
caspase-8 activation – for all variants tested – as well as by
the involvement of cFLIP and Bid signaling molecules
characteristic of the extrinsic apoptotic pathway. The over-
expression of DR4 and DR5 after Ab challenge together
with the membrane colocalization of the receptors with Ab
homologs and the protective effect achieved after knocking
down DR4 and DR5 unquestionably established the partici-
pation of both receptors in EC Ab-induced apoptosis. Death
receptors of the TNFR family have been previously implicated
in Ab-mediated neuronal cell responses. Both the p75
neurotrophin receptor and TNF-a receptors mediated Ab42-
induced neuritic dystrophy and neuronal death
19,20 while
antibody-mediated blockade of DR5 prevented the toxicity
on neuronal SHSY5Y cells of a non-physiological Ab
fragment.
21 Supporting a mechanistic involvement of apop-
totic extrinsic pathways in AD pathogenesis, both Ab and
APP were shown to activate neuronal death receptor signal-
ing through direct binding to p75 and DR6.
22,23 Our data
unveils, for the ﬁrst time, the involvement of death receptors
2h 4h 8h
Aβ
2h 4h 8h
DR4
2h 4h 8h
Merge
Figure 5 Analysis of DR4 upregulation and colocalization with Ab after short-term treatment with Ab-E22Q. ECs were treated with AbE22Q (50mM) for 2, 4, or 8h, and
colocalization of the peptide with the DR4 receptor was analyzed by immunoﬂuorescence and confocal microscopy. Green signal indicates DR4 and Ab is highlighted in red.
Blue represents nuclei visualized with TO-PRO. In all cases, bar represents 25mm
DR4/DR5 mediate oligomeric Ab-induced EC apoptosis
S Fossati et al
7
Cell Death and Diseaseon the oligomeric Ab-induced apoptosis in brain vascular
cells pinpointing to DR4 and DR5 as major players in CAA-
related dysfunction.
The unique role of TRAIL death receptors in the nervous
system is highlighted by the widespread expression of DR4
and DR5 in many cell types in the human brain, including
neurons, astrocytes, oligodendrocytes, and EC, as well as by
DR5 overexpression in AD.
21 In contrast to the ample
distribution of DR4 and DR5, their physiological ligand,
TRAIL, is not constitutively produced in the brain, and its
release has been only reported during neuroinﬂammation.
16
The current ﬁndings reveal a novel mechanism by which brain
cells – through the engagement of the receptors upon binding
to Ab oligomers – become susceptible to DR4- and DR5-
mediated apoptosis, in absence of their typical ligand.
Physiologically, death receptors are activated by binding to
their speciﬁc ligands either previously released into the
extracellular space or expressed as membrane components
in the same or in different cells. It is, however, not uncommon
for certain death receptors that the activation of downstream
signaling cascades takes place independently of their
canonical ligand mainly through upregulation and clustering
of the receptors.
24–26 Indeed, receptor density, distribution,
and clustering are key spatial features that inﬂuence effective
physical and biochemical cellular responses. In this sense,
Fas–Fas bridge formation, stabilized upon clustering, leads to
a sufﬁcient number of Fas molecules in close proximity, as
occurring after traditional Fas–ligand binding.
27 Particular
attention has been given lately to the generation of high
receptor densities involving plasma membrane microdomains
known as lipid rafts. These platforms are postulated to
have important roles in membrane protein trafﬁcking and
receptor-speciﬁc signaling.
28,29 In the case of AD, lipid rafts
appear to serve as a stage for various processes related to
the disease pathogenesis including secretase activity and
APP processing as well as Ab ﬁbrillization, neuronal
Q22 F
DR4 DR5 Fas Fc
Q22 F
DR4 DR5 Fas Fc
V34 F V34 3d
DR4 DR5 Fc DR5 Fc
V34 F V34 3d
DR4 DR5 Fc DR5 Fc
Bound Input Input Bound
AβWT F AβWT 3d
DR4 DR5 Fc DR4 DR5 Fc
AβWT F AβWT 3d
DR4 DR5 Fc DR5 Fc DR4 DR5 DR5 AβWT Aβ40-1
AβWT 3d
Bound Input Bound Input
DR4 DR4
DR4 DR4
Aβ40-1
Figure 6 Bindingof Ab variantsto deathreceptor-Fcchimeras. Ab homologs– eitherfreshlysolubilized(F)or pre-aggregatedfor 3days(3d) –wereimmunoreacted with
paramagnetic beads coupled to DR4/Fc (DR4), DR5/Fc (DR5), and Fas/Fc (Fas) chimeras, as well as to the IgG-Fc fragment employed as negative control for nonspeciﬁc
binding. Immunoprecipitated material was eluted under non-denaturing conditions and analyzed by WB after native 5–30% gradient gel electrophoresis. In all cases, bound
panels represent the immunoprecipitated material speciﬁcally retained by the respective immobilized receptor chimeras; input panels illustrate the oligomerization state of the
starting material incubated with the respective immobilized chimeras. Results are representative of at least three experiments. (a)A b-E22Q (Q22), (b)A b-L34V (V34),
(c)A b–WT, and (d) reverse Ab40-1 used as negative control and previously conjugated to biotin to allow WB detection as anti-Ab 4G8 and 6E10 antibodies are not
immunoreactive with the reverse sequence peptide. This panel also illustrates – for control purposes– binding of biotin-conjugated Ab-WT to DR4 and DR5; both biotinylated
peptides were pre-aggregated for 3 days before binding to the receptor chimeras. In (d), WB was probed with streptavidin-HRP as detector reagent. In all cases, ﬂuorograms
were developed by chemiluminiscence
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30 In the case of DR4
and DR5, their redistribution into lipid rafts has been shown to
facilitate the formation of DISCs and downstream caspase
activation.
31 Whether the observed membrane colocalization
of Ab with DR4 and DR5 in our system reﬂects the interaction
with lipid components or relies onthe association with lipid raft
microdomains remain to be further elucidated.
Direct binding to multivalent ligands is another mechanism
capable of causing receptor clustering and initiating down-
stream signaling. In fact, multivalent presentation typically
enhances the afﬁnity and speciﬁcity of a wide array of
interactions. Through speciﬁc structural features including
high density and a particular arrangement of binding sites,
multivalent ligands exhibit unique capabilities to cluster
receptors.
32 In the case of Ab, oligomerization confers the
peptide potent effects for neuronal cells – inducing synaptic
disruption and neurotoxicity
33 – and for vessel-wall cells –
initiating rapid apoptotic pathways.
5,10,34,35 Ab multimeriza-
tion is also important for receptor activation. Ab oligomers act
as an extracellular scaffold for the group 1 metabotropic
glutamate receptor 5 (mGluR5), resulting in the receptor
clustering and stabilization and inducing synaptic failure.
36
Binding to multivalent molecules such as speciﬁc antibodies
ormultivalentpeptidesisalsoawell-establishedwaytotrigger
DR4 and DR5, a feature that is currently being explored for
therapeutic potential in cancer treatment clinical trials.
37 Our
data bridge together the aggregation potential of Ab and the
capability of Ab oligomers to speciﬁcally bind DR4 and DR5
with the requirement of both receptors for clustering to induce
downstreamsignaling pathways.Bydelineatingthemolecular
mechanisms elicited by Ab oligomers in cerebral EC, our work
unveils new targets for pharmacological intervention in
amyloid-induced vessel-wall apoptosis.
Materials and methods
Ab peptides. Synthetic homologs of the amyloid subunits present in the
vascular deposits in sporadic and familial Dutch- and Piedmont-AD cases – wild-
type (WT) Ab40 and the genetic variants containing the E22Q and L34V
substitutions, respectively, as well as the reverse sequence Ab40-1 peptide –
were synthesized using N-tert-butyloxycarbonyl chemistry by James I Elliott at
Yale University. Ab homologs were dissolved to 1mM in 1,1,1,3,3,3-hexaﬂuoro-
2-propanol (HFIP; Sigma, St. Louis, MI, USA), incubated for 12h to breakdown
pre-existing b-sheet structures,
5 and lyophilized. Peptides were subsequently
dissolved in DMSO to a 10-mM concentration, followed by the addition of
deionized water to 1-mM concentration, and further dilution into culture media
to the required concentrations for the different experiments.
Biotinylation of Ab-WT and reverse Ab40-1 peptides for the receptor-chimera-
binding studies was performed after HFIP pre-treatment using sulfo-NHS-biotin
(Thermo Fisher Scientiﬁc, Rockford, IL, USA) as previously described in our
laboratory.
38 Biotin-labeled peptides were concentrated and separated from free
biotin using 3-kDa cutoff Centricon centrifugal ﬁlter devices (Millipore, Billerica,
MA, USA).
Cell cultures. Immortalized human brain microvascular ECs HCMEC/D3 were
obtained from Babette Weksler
39 and maintained in complete EBM-2 medium
(Lonza, Allendale, NJ, USA) added of growth supplements and 2.5% fetal bovine
serum (FBS). This cell line retains the morphological characteristics of primary
brain ECs and expresses speciﬁc brain endothelial markers and cell surface
adhesion molecules.
Caspase-8 and -9 activity assays. Caspase activation was measured
by luminescent assays (Caspase-Glo 8 and Caspase-Glo 9, Promega, Madison,
WI, USA), in cells treated with the Ab variants in EBM-2/1% FBS. Brieﬂy, 10000
cells/well were plated in 96-well plates and incubated for 0–24h with the
Ab peptides either freshly solubilized in the case of E22Q or pre-aggregated
at 371C for 3 days for L34V and Ab40-WT. Caspase-Glo reagent was
added to the cell cultures resulting in cell lysis, followed by caspase cleavage
of the substrate and generation of a luminescent signal produced by the
luciferase reaction. After 40-min incubation the signal, proportional to the amount
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Figure 7 Protection from Ab-induced apoptosis by DR4 and DR5 gene
silencing. (a) qRT-PCR performed after siRNA delivery of two control genes
(GAPDH and Cyclophilin B; top panel) as well as DR4 and DR5 (bottom panel)
demonstrate the efﬁciency and speciﬁcity of the EC-silencing approach.
(b) Quantitation of EC apoptosis following challenge with Ab-E22Q (Q22, 1 day,
25mM) was evaluated by cell death ELISA, after silencing the expression of DR4,
DR5, or both receptors. (c) Quantitation of caspase-8 activation (Caspase Glo-8)
following EC challenge with Ab-E22Q (25mM; 6h) after silencing the expression of
DR4andDR5.Inboth(bandc),siNCrepresentsthenon-targetingsiRNAusedasa
negative control and results are expressed as fold of increase compared with
controls in absence of E22Q. Graphs in (b and c) represent the mean±S.D. of two
separate experiments, each one in duplicate. *
,** indicate statistically signiﬁcant
differences, Pr0.05 and Po0.01, respectively, for amyloid-challenged cells in
the presence of DR4 and DR5 siRNA compared with siNC
DR4/DR5 mediate oligomeric Ab-induced EC apoptosis
S Fossati et al
9
Cell Death and Diseaseof caspase activity present, was evaluated in a plate-reading luminometer
(Synergy HT Multi-Mode Microplate Reader, Biotek, Winooski, VT, USA). To inhibit
nonspeciﬁc background activity, the proteasome inhibitor MG-132 was added
to the Caspase-Glo reagent before the experiment as indicated by the
manufacturer. In all cases, results are expressed as fold change compared with
untreated control cells.
Western blot. Evaluation of cFLIP as well as full-length and tBid expression
was performed using WB analysis after electrophoretic separation on 12% SDS
polyacrylamide gels. Proteins were electrotransferred to PVDF membranes
(0.45mm pore size; Immobilon, Millipore) at 400mA for 1.5h, using 10mM
3-cyclohexylamino-1-propanesulfonic acid (CAPS, Sigma) buffer, pH 11.0,
containing 10% (v/v) methanol. Membranes were blocked with 5% non-fat milk
in PBS containing 0.1% Tween 20, and subsequently immunoreacted with
polyclonal rabbit antibodies recognizing cFLIP and human Bid (1:2000 and
1:1000, respectively; Cell Signaling/Millipore, Billerica, MA, USA), as well as
monoclonal antibody against GAPDH (Imgenex, San Diego, CA, USA) as a
loading control, followed by the pertinent horseradish peroxidase (HRP)-labeled
anti-rabbit or anti-mouse IgG (1/5000 or 1/10000, respectively; GE Healthcare Life
Sciences, Pittsburgh, PA, USA). Fluorograms were developed by enhanced
chemiluminescence (ECL) with ECL western blotting detection reagent (GE
Healthcare Life Sciences), and exposed to Hyperﬁlm ECL (GE Healthcare Life
Sciences).
For the assessment of Ab binding to DR4-Fc, DR5-Fc, and Fas-Fc chimeras
(R&D Systems, Minneapolis, MN, USA), proteins were electrophoretically
separated under native conditions using 5–30% gradient polyacrylamide gels, in
theabsenceofSDS,employing25mMTris/glycinebuffer,pH8.8,asrunningbuffer.
Molecular mass markers for native gel electrophoresis consisted of proteins with
acidic isoelectric point: human albumin, ovoalbumin, soybean trypsin inhibitor,
lactoglobulin, and insulin. After transferring for 2.5h at 400mA, as above,
membranes were incubated with a combination of mouse monoclonal anti-Ab
antibodies 4G8 (epitope: residues Ab18-22) and 6E10 (epitope: residues Ab3-8),
bothfromCovance(Princeton,NJ,USA),at1:3000dilutioneach,followedbyHRP-
labeled anti-mouse IgG and ECL chemistry, as above. Molecular masses of Ab
oligomericassemblieswereestimatedbasedintheirrelativemobilitycomparedwith
standards following linear regression and Ferguson plot analysis with the aid of
GraphPad Prism software (GraphPad, La Jolla, CA, USA), as we previously
described.
40
PCR arrays and quantitative RT-PCR. Human apoptosis-speciﬁc PCR
arrays (SABiosciences, Qiagen, Valencia, CA, USA) were performed in EC
challenged with Ab40-E22Q peptide for 6h. After isolation of the RNA and
retrotrascription, RT-PCR of the 384-well arrays was performed using an ABI 7900
SDS system (Applied Biosystems, Carlsbad, CA, USA) at New York University
Genomics Facility. Data analysis was performed using RT
2 Proﬁler PCR Array
Data Analysis software (SABiosciences). Quantitative RT-PCR for evaluation of
TNFRSF10A (DR4) and TNFRSF10B (DR5) receptors, as well as the internal
controls b-Actin, GAPDH, and cyclophilin B, was performed with the same
instrument using the oligonucleotide primers described below custom synthesized
at Gene Link (Hawthorne, NY, USA). DR4: 50-TCCAGCAAATGGTGCTGAC-30 (F)
and 50-GAGTCAAAGGGCACGATGTT-30 (R); DR5: 50-CCAGCAAATGAAGGTGA
TCC-30 (F) and 50-GCACCAAGTCTGCAAAGTCA-30 (R); b-actin 50-TGGACATC
CGCAAAGACCTG-30 (F) and 50-CCGATCCACACGGAGTACTT-30 (R); GAPDH:
50-TGCACCACCAACTGCTTAG-30 (F) and 50-GGATGCAGGGATGATGTT-30 (R);
cyclophilin-B 50-GATGGCACAGGAGGAAAGAG-30 (F) and 50-AGCCAGGCTGTC
TTGACTGT-30 (R).
Immunocytochemical evaluation of DR4 and DR5 expression.
EC were plated on glass chamber slides (Thermo Fisher Scientiﬁc), precoated with
type-I collagen (Sigma), and allowed to rest for 1 day before treatment with the
different peptides, as above, for 2h to 3 days. Cells were ﬁxed with 4%
paraformaldehyde, incubated with monoclonal antibodies recognizing TRAIL-R1
(DR4) and TRAIL-R2 (DR5) (Alexis Biochemicals, San Diego, CA, USA ; 1:200 in
PBS containing 0.1% Tween 20 and 5mg/ml BSA (PBST/BSA)) followed by Alexa
Fluor 488-conjugated anti-mouse IgG (Invitrogen, Carlsbad, CA, USA; 1:200 in
PBST/BSA). Ab peptides were stained using rabbit polyclonal anti-Ab40
(Invitrogen, 1:200 in PBST/BSA), followed by Alexa Fluor 568-conjugated anti-
rabbit IgG. Nuclei were counterstained with To-pro (Invitrogen). Speciﬁcity of
immune detection was corroborated by omission of the primary antibody in the
immunostaining procedure. In all cases, imaging was performed in a Zeiss LSM
510 laser scanning confocal/Confocor2 microscope using a 40  DIC oil
immersion objective and LSM 510 software; acquired images were imported into
ImageJ (National Institute of Health; http://rsbweb.nih.gov/ij/).
Quantitative evaluation of TRAIL by ELISA. Production of TRAIL
following treatment with the different Ab peptides was evaluated using
a speciﬁc ELISA (Quantikine Human TRAIL Immunoassay; R&D Systems).
A
FADD
Pro-
CASP
8
FADD
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tBID
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Figure 8 Proposed apoptotic changes elicited in cerebral ECs by Ab oligomers. The diagram summarizes the postulated apoptotic transformations induced by Ab
oligomeric assemblies in cerebral EC. Ab oligomers, interacting with membrane receptors DR4 and DR5, trigger activation of caspase-8, which operates cleavage of Bid into
tBid. The truncated form of Bid, interfering in the equilibrium between Bcl-2 and Bax, induces the release of CytC from the mithochondria. Cytosolic CytC stimulates the
activation of caspase-9 that, in concurrence with caspase-8, induces downstream activation of caspase-3 promoting the ﬁnal execution of apoptosis
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6 cells/well were seeded on 6-well plates and cultured for 1 day, as
above, before treatment with the peptides (50mM in 1ml of EBM-2 containing
1% FBS). After 1- and 3-day incubation, conditioned media was collected, cells
lysed, and both supernatants and lysates tested for TRAIL expression by capture
ELISA, following the manufacturer’s speciﬁcations. Final color was evaluated at
450nm, with reference wavelength set at 540nm, on a Spectracount microplate
reader (Packard, Meriden, CT, USA). Concentration of TRAIL was determined
through the use of a standard curve generated with recombinant protein provided
with the kit.
Binding of Ab40 variants to death receptor-Fc chimeras. Direct
binding of Ab homologs to the death receptors DR4, DR5, and Fas was
evaluated through incubation of the different peptides with protein chimeras of the
respective receptors with the IgG Fc fragment immobilized onto Protein-G-coated
paramagnetic beads. Brieﬂy, Protein-G-coated Dynabeads (Invitrogen; 50ml) were
separately incubated for 20min with 3mg each of DR4-Fc, DR5-Fc, or Fas-Fc protein
chimeras (R&D systems), as well as human IgG-Fc (Bethyl Laboratories,
Montgomery, TX, USA), which was used as negative control for nonspeciﬁc binding.
After washing, the receptor-coated magnetic beads were further incubated for 30min
at RT with Ab-E22Q, -L34V, or -WT (either fresh, in the case of E22Q, or pre-
aggregated for 3 days, for the other two peptides; all at 50mM concentration in EBM-
2 medium). After magnetic separation of the beads, supernatants were discarded,
and the beads washed three times with PBS containing 0.1% Tween 20. The IP
material was eluted from the paramagnetic beads by short incubation (2min) with a
non-denaturing elution buffer (Glycine pH 2.8). Both the peptides used as starting
material (input), and fractions bound to the immobilized receptors (bound) were
separated in native 5–30% gradient gel electrophoresis and analyzed by WB probed
with a combination of 4G8 and 6E10 anti-Ab antibodies, as described above. To
conﬁrm the speciﬁcity of Ab binding to DR4/DR5, the immobilized receptor chimeras
were incubated with biotin-conjugated reverse Ab40-1, pre-aggregated for 3 days.
Both the starting material (input) and bound fractions were analyzed by WB probed
with streptavidin-HRP (Life Technologies/Invitrogen, Carlsbad, CA, USA) followed by
ECL as above.
DR4 and DR5 gene silencing. Silencing of DR4 and DR5 was performed
through passive siRNA delivery via Accell SMART pool siRNA (Thermo Scientiﬁc-
Dharmacon, Rockford, IL, USA), following the manufacturer’s protocol. Brieﬂy,
2000 cells/well – plated in 96-well dishes – were treated separately with the
respective siRNA solutions constituted by each siRNA pool as well as a
ﬂuorescent non-targeting siRNA, employed as negative control, diluted in Accell
delivery media to a 1mM ﬁnal concentration. The efﬁciency and speciﬁcity of the
DR4 and DR5 silencing as well as the GAPDH and Cyclophilin B controls were
tested by RT-PCR. To assess the effect of DR4 and DR5 silencing on Ab-induced
toxicity, cells were pre-incubated 64h in the siRNA-containing media and
subsequently challenged with Ab-E22Q (25mM in the same culture media
containing siRNA); caspase-8 activation and apoptosis induction were evaluated
after 6h and 24h, respectively. The level of DR4/DR5 receptor silencing after
E22Q challenge was monitored by qRT-PCR on a parallel set of control cells, as
described above.
Cell death ELISA. The extent of apoptosis caused by Ab in the presence or
absence of the respective siRNAs was assessed by quantitation of nucleosome
formation using Cell Death ELISA (Roche Applied Science, Indianapolis, IN, USA).
Brieﬂy, after siRNA and incubation with E22Q peptide, plates were centrifuged
in a Beckman J-6B centrifuge(10min;1000r.p.m.), cells lysed, and DNA-histone
complexes (nucleosomes) quantitated by Cell Death ELISA, as previously
described.
5,34
Statistical analysis. Analysis of variance for multiple comparison tests and
Tuckey’s post-hoc test were performed using GraphPad InStat (GraphPad
Software). Statistical signiﬁcance was set at Pr0.05.
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